However, BRAF mutations alone are not sufficient for BMs to occur, and there is proof that PTEN gene silencing cooperates with BRAFV600E mutations in melanoma progression via the phosphoinositide 3-kinase (PI3K)/AKT pathway activation [104]. The gene discussed is PTEN; the disease is melanoma.